首页> 外文期刊>Clinical immunology: The official journal of the Clinical Immunology Society >B cell tumor vaccine enhanced by covalent attachment of immunoglobulin to surface proteins on dendritic cells.
【24h】

B cell tumor vaccine enhanced by covalent attachment of immunoglobulin to surface proteins on dendritic cells.

机译:B细胞肿瘤疫苗通过免疫球蛋白与树突状细胞表面蛋白的共价结合而增强。

获取原文
获取原文并翻译 | 示例
           

摘要

Protein antigens have been covalently linked randomly to surface proteins on immature dendritic cells (DC). This has been achieved under physiological conditions using a heterobifunctional reagent that couples antigens to free thiol groups expressed on DC surface proteins. This results in a significant increase in the amount of antigen that is bound to DC, and the antigen/membrane protein complexes that are formed are rapidly internalized. DC, loaded covalently with either beta-galactosidase (beta-gal) or a tumor-associated immunoglobulin (Ig) when injected into mice, induce a beta-gal- or Ig-specific T cell response, and a protective anti-tumor immunity for tumors expressing either beta-gal or the targeted Ig. This response is shown here to be significantly greater than that which is induced by DC that are loaded with these antigens via the conventional antigen pulse protocol. These results establish a novel, safe, and viable approach of enhancing the effectiveness of DC-based vaccination strategies for B cell lymphoma.
机译:蛋白抗原已经随机地与未成熟树突状细胞(DC)上的表面蛋白共价连接。这是在生理条件下使用异双功能试剂实现的,该试剂将抗原与DC表面蛋白上表达的游离巯基偶联。这导致与DC结合的抗原数量显着增加,并且形成的抗原/膜蛋白复合物迅速内在化。将DC注射到小鼠体内时共价装有β-半乳糖苷酶(β-gal)或肿瘤相关免疫球蛋白(Ig),可诱导β-gal-或Ig特异性T细胞应答,并具有针对性的抗肿瘤免疫力表达β-gal或靶向Ig的肿瘤。在此显示该应答明显大于通过常规抗原脉冲方案由负载有这些抗原的DC诱导的应答。这些结果建立了一种新颖,安全和可行的方法来增强针对B细胞淋巴瘤的基于DC的疫苗接种策略的有效性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号